The Church of Gaia announced on Friday that it has been “granted the first-ever approval for a Petition for Religious Exemption from the Controlled Substances Act (CSA) pursuant to the Religious Freedom Restoration Act (RFRA).” This exemption permits the Church to legally use Ayahuasca in its religious ceremonies, making it one of only a handful
Facilitating International Psychedelic Retreats
A potential expansion of the religious use of psychedelic substances
I am thrilled to share that I will be moderating a Table Topic on the impact of psychedelics legalization on trademark law at the International Trademark Association’s (INTA) 2025 Annual Meeting in San Diego! The session will take place Tuesday, May 20, 2025, from 8:00 AM – 10:00 AM (PST). With the increasing legalization of
Ninth Circuit sides with DEA on doctors petition to seek waiver under Right to Try laws
The end of 2024 marks two years in the books for the Oregon Psilocybin Services (OPS) program. It has been a long road: in my year-end 2023 post, I explained that the program was incubated on a protracted, two-year runway prior to launch. This mean we are four years along, with two years of live
Over the last few weeks, the federal government has taken a number of actions that signal a dark future for psychedelic therapies. Today we’ll take a quick look at what’s happened, and what may happen in the future. FDA gives thumbs down to MDMA Earlier in August, the FDA opted not to approve Lykos Therapeutics’
Happy 4th of July from all of us here at the Psychedelics Law Blog! We hope you have a fun, safe and not-too-hot holiday with family and friends. We will be back soon with our regular programming.
Oregon’s rule limiting the non-resident ownership of licensed psilocybin businesses sunsets on December 31, 2024. That’s a little over six months away. Six months is not that long, especially in the context of getting to know an industry or a business, and putting a thoughtful deal together– one that will generate reasonable returns for an
A new age for psychedelics We are on the verge of a psychedelic renaissance, with the Food and Drug Administration (FDA) accepting a new drug application for midmafetamine (MDMA) in February of this year. MDMA the active ingredient in the common party drug “ecstasy” or “molly”. If approved, the drug would be used to treat
